Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART

2 Jul 2019

Abstract excerpt

BACKGROUND: We previously demonstrated that etonogestrel concentrations were 82% lower in women using etonogestrel contraceptive implants plus efavirenz-based ART compared with women not receiving ART. OBJECTIVES: To investigate the genetic contribution to this previously observed drug-drug interaction through studying SNPs in genes known to be involved in efavirenz, nevirapine or etonogestrel metabolism in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to Pharmacological Effects and Toxicity Studies
Share to Reproductive Health and Contraception

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31299074
DOI: 10.1093/jac/dkz298

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ARTPMID 31299074Read ↗

The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.Semantic proximity Read ↗

Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.Semantic proximity Read ↗

Efavirenz and CYP2B6 Polymorphism: Implications for Drug Toxicity and ResistanceSemantic proximity Read ↗

A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Semantic proximity Read ↗

Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review.Semantic proximity Read ↗

Pharmacogenetics of antiretroviral therapy.Semantic proximity Read ↗

Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments.Semantic proximity Read ↗

Gene-gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

Pharmacogenomics of Antiretroviral Drug Metabolism and TransportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.